Limited in Medical Technology

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

New Bisphenol A Study Is of Very Limited Relevance to Human Health

... public health. To achieve these goals with limited resources, including limited use of laboratory animals, study designs should ... been acknowledged by the NIEHS to have very limited value for assessing human health effects since ...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

... risks and uncertainties including, but not limited to, the risk that the rate of objective tumor ... for its product candidates include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

... Examples of such statements include, but are not limited to, the extension of marketing exclusivity for ... risks and uncertainties, including, but not limited to; positive results in clinical trials may not ... regulatory approvals which are received may be limited to certain indications; NeurogesX' product ...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

... risks and uncertainties including, but not limited to, the risk that the rate of objective tumor ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

... blockages can result in severe pain for patients, limited physical mobility, and life-threatening ... Act of 1995. Such statements include, but are not limited to, statements about the success, design, ... risks and uncertainties include, but are not limited to, in no particular order: the success of ...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

... risks and uncertainties including, but not limited to, the risk that results from future preclinical ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... risks and uncertainties including, but not limited to the risk that results from future preclinical ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

... risks and uncertainties including, but not limited to, the risk that the rate of objective tumor ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'

... and limit mobility. Treatment is generally limited to bed rest and pain medication. Repeated fractures often result, leading to stooped backs, limited mobility and depression. By inserting and ... thought and that this complication is not limited to young patients. Chondrolysis can follow the ...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

... its parent company Takeda Pharmaceutical Company limited (TSE:4052) today announced the Independent Data ... in Osaka, Japan, Takeda Pharmaceutical Company limited (TSE:4502) is a research-based global company ... was acquired by Takeda Pharmaceutical Company limited in May 2008. The Company's research, development ...

Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs

... bovine and rabbit eggs are capable of supporting limited cell division, specific reprogramming towards the ... is achieved, clinical trials are likely to be limited to immune-privileged sites in the body, such as ... by such forward-looking statements, including: limited operating history, need for future capital, risks ...

NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology

... Examples of such statements include, but are not limited to, the expected timing of regulatory decisions ... risks and uncertainties, including, but not limited to, NeurogesX' product candidates may have ... approvals which are received may offer more limited indications than anticipated; physician or ...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... inhibitors should be avoided (including, but not limited to, ketoconazole, itraconazole, clarithromycin, ... inducers should be avoided (including, but not limited to, dexamethasone, phenytoin, carbamazepine, ... (Ph+ CML) in the chronic phase. Follow-up is limited to 5 years. Gleevec is also indicated for ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... leukemia (CML) in the chronic phase. Follow-up is limited to 5 years. Gleevec is also indicated for ... inhibitors should be avoided (including, but not limited to, ketoconazole, itraconazole, clarithromycin, ... inducers should be avoided (including, but not limited to, dexamethasone, phenytoin, carbamazepine, ...

Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD

... The risks and uncertainties include, but are not limited to, risks associated with: the inherent ... and commercialization including, but not limited to, the establishment in the market of VYVANSE(R) ... of competitive products, including, but not limited to, the impact of those on the Company's ...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

... The risks and uncertainties include, but are not limited to, risks associated with: the inherent ... and commercialization including, but not limited to, the establishment in the market of VYVANSE(R) ... of competitive products, including, but not limited to, the impact of those on the Company's ...

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial

... risks and uncertainties including, but not limited to, the risk that the company will ... results to differ materially include, but are not limited to, uncertainties associated with ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine

... new diagnosed patients globally per year and only limited treatment options. With estimated more than ... PROSTVAC(TM) into phase III trials will have a limited financial impact on year 2009, which will be ... currently used to treat prostate cancer has limited survival rates and is often associated with ...

Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial

... gout is a treatable condition, there are limited treatment options and a number of adverse effects ... NNRTIs; a high genetic barrier to resistance; limited pharmacokinetic interactions with other drugs; no ... Such statements include, but are not limited to, statements regarding our goals, including the ...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

... risks and uncertainties including, but not limited to, the risk that the company will ... results to differ materially include, but are not limited to, uncertainties associated with ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent

... call at 11am BST/6am EDT - details below Shire limited (LSE: SHP, NASDAQ: SHPGY), the global ... The company pursues disease indications that have limited or no treatment options and has built a drug ... Deutsche Bank are acting as advisers to Shire limited and Credit Suisse are acting as advisers to ...

Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer

... risks and uncertainties including, but not limited to, the risk that the results of the ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Silence Therapeutics Announces Board Changes

... Sinclair Pharma plc Kinneir Dufort limited Avantis (UK) Ltd Maggiore Ventures limited Operation Smile (UK) Limited Past Directorships: Pharmadiligence limited Crisp ...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

... risks and uncertainties including, but not limited to the risk that the company will ... results to differ materially include, but are not limited to, uncertainties associated with ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... risks and uncertainties including, but not limited to, the risk that dose-limiting toxicities may be ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil

... May 27 /PRNewswire-FirstCall/ -- Shire limited (LSE: SHP, NASDAQ: SHPGY), the global specialty ... research, product development including, but not limited to the successful development of JUVISTA(R) ... ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD ...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

... research, product development including, but not limited to the successful development of JUVISTA(R) ... ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD ... regulation and approval, including but not limited to the expected product approval date of ...

Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047

... /PRNewswire-FirstCall/ -- Progen Pharmaceuticals limited (ASX:PGL; Nasdaq: PGLA) today announced that ... Justus Homburg, CEO Progen Pharmaceuticals limited T: +61 7 3842 3333 E: ... Relations Manager Progen Pharmaceuticals limited T: +61 7 3842 3333 E: cindyi@progen-pharma.com ...

Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists

... research, product development including, but not limited to the successful development of JUVISTA(R) ... and commercialization including, but not limited to, the establishment in the market of ... ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD ...

New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months

... research, product development including, but not limited to the successful development of JUVISTA(R) ... and commercialization including, but not limited to, the establishment in the market of ... ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD ...

Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

... research, product development including, but not limited to the successful development of JUVISTA(R) ... and commercialization including, but not limited to, the establishment in the market of ... ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD ...

Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting

... research, product development including, but not limited to the successful development of JUVISTA(R) ... and commercialization including, but not limited to, the establishment in the market of ... ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD ...

Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy

... research, product development including, but not limited to the successful development of JUVISTA(R) ... ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD ... regulation and approval, including but not limited to the expected product approval date of ...

Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced

... in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common ... in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common ... continued review of Phase II data and the limited number of patients studied to date; additional ...

Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

... significant anti-inflammatory activity, and have limited potential for central nervous system ... including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may ... Such statements include, but are not limited to, statements regarding: sufficiency of cash ...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

... risks and uncertainties including, but not limited to, the risk that the company will ... results to differ materially include, but are not limited to, uncertainties associated with completing ... in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ...

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

... its partner, Glenmark Pharmaceuticals limited (BSE: Glenmark). The primary endpoints of the ... has partnerships with Glenmark Pharmaceuticals limited of India and AsiaPharm Group Ltd. of China. For ... Crofelemer acts locally in the intestines, with limited systemic exposure. ...

Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients

... research, product development including, but not limited to the successful development of JUVISTA(R) ... ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD ... regulation and approval, including but not limited to the expected product approval date of ...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... administration of IGIV has been limited by the inability of the tissue to absorb large ... occurred. Administration time and flow rates were limited by pump characteristics and not by patient ... humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common ...